AVITA Medical Inc
NASDAQ:RCEL

Watchlist Manager
AVITA Medical Inc Logo
AVITA Medical Inc
NASDAQ:RCEL
Watchlist
Price: 11.77 USD 2.53% Market Closed
Market Cap: 308.6m USD
Have any thoughts about
AVITA Medical Inc?
Write Note

P/OCF
Price to OCF

-6
Current
-8.7
Median
21.9
Industry
Higher than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-6
=
Market Cap
308.6m USD
/
Operating Cash Flow
-51.7m USD
All Countries
Close
Market Cap P/OCF
US
AVITA Medical Inc
NASDAQ:RCEL
308.6m USD -6
FR
Pharnext SCA
OTC:PNEXF
6T USD -239 042.4
US
Abbvie Inc
NYSE:ABBV
310.3B USD 18.8
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 19.5
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD -121.5
US
Epizyme Inc
F:EPE
94.1B EUR -470.6
AU
CSL Ltd
ASX:CSL
133.7B AUD 30.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 18.2
US
Seagen Inc
F:SGT
39.3B EUR -76
NL
argenx SE
XBRU:ARGX
36.2B EUR -145.3
 
US
AVITA Medical Inc
NASDAQ:RCEL
Average P/OCF: 19.6
Negative Multiple: -6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -239 042.4
US
Abbvie Inc
NYSE:ABBV
18.8
US
Amgen Inc
NASDAQ:AMGN
19.5
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -121.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -470.6
AU
CSL Ltd
ASX:CSL
30.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -76
NL
argenx SE
XBRU:ARGX
Negative Multiple: -145.3

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A

See Also

Discover More